论文部分内容阅读
概述钙通道阻滞剂也称钙拮抗剂(以下简称CEB)为过去十余年在心血管疾病治疗中的巨大进展。1963年Fleckenstein在鉴定异搏停及双苯丙胺时发现它们可抑制心肌兴奋一收缩偶联,从而提出了钙拮抗机制。以后通过对硝苯吡啶(心痛定)等药物的鉴定,发现这些药物也有类似作用,1969年他宣布发现了一类可抑制心肌兴奋一收缩偶联的“钙拮抗剂”。1972年拜尔药厂的商品药物Adalat(心痛定)问世,最近十余年CEB的研究与临床应用有了飞速发展,迄1984年国外40多个药厂至少开发51个药物,1985年
Overview Calcium channel blockers, also known as calcium antagonists (hereinafter referred to as CEB), represent a tremendous advance in the treatment of cardiovascular disease over the past decade. In 1963 Fleckenstein in the identification of verapamil and amphetamine found that they can inhibit cardiac excitation-contraction coupling, which proposed the mechanism of calcium antagonism. After the identification of nifedipine (nifedipine) and other drugs, found that these drugs have a similar effect, in 1969 he announced the discovery of a class of inhibition of cardiac excitation-contraction coupling of a “calcium antagonist.” In 1972 Bayer Pharmaceuticals commercial drug Adalat (heartache given) came out, the last ten years CEB research and clinical application has been rapid development, as of 1984, more than 40 pharmaceutical companies to develop at least 51 drugs, 1985